Tolerance Bio licenses anti-IL-33 antibody from Tanabe Pharma
Tolerance Bio said it secured exclusive worldwide development rights and non-Japan commercialization rights for Tanabe Pharma's TLB-33, a clinical-stage anti-IL-33 monoclonal antibody. The license includes potential development and sales milestone payments of up to about $560 million, plus equity consideration and roya